Radiation and Brachytherapy for Cervical Cancer: What India's Top Centres Actually Deliver

External beam radiation alone is not enough. Brachytherapy — the part most women in Africa and South Asia cannot access at home — is what makes the difference between curative and inadequate treatment. This guide explains how IMRT, image-guided adaptive brachytherapy, and concurrent cisplatin work together, what the evidence shows about outcomes, and why India's top centres deliver this treatment at 90% lower cost than the US.

By Gaf Healthcare Editorial Team

2026-05-10

<!DOCTYPE html> <html lang="en"> <head> <meta charset="UTF-8"> <meta name="viewport" content="width=device-width, initial-scale=1.0"> <title>Radiation and Brachytherapy for Cervical Cancer: What India's Top Centres Actually Deliver</title> <meta name="description" content="Radiation and brachytherapy for cervical cancer explained. See how India's top centres deliver IGRT and HDR brachytherapy to international standards — and what it costs vs the US and UK."> <link rel="preconnect" href="https://fonts.googleapis.com"> <link href="https://fonts.googleapis.com/css2?family=Lora:ital,wght@0,400;0,600;1,400&family=Source+Sans+3:wght@400;500;600&display=swap" rel="stylesheet"> <style> , ::before, ::after { box-sizing: border-box; margin: 0; padding: 0; } :root { --cream: #F5F2EB; --cream-dark: #EDE9DF; --green-dark: #1B5E3B; --green-mid: #2D7A52; --green-light: #EAF4EE; --green-border: #C2DFCC; --red-accent: #B84040; --red-bg: #FDF2F2; --amber: #B07A15; --amber-bg: #FDF7EC; --amber-border: #E8D5A0; --text-primary: #1A1A18; --text-body: #2E2E2A; --text-muted: #6B6860; --text-green: #1B5E3B; --border-soft: #DDD9CF; } body { font-family: 'Source Sans 3', sans-serif; background-color: var(--cream); color: var(--text-body); font-size: 18px; line-height: 1.75; -webkit-font-smoothing: antialiased; } .page-wrap { max-width: 740px; margin: 0 auto; padding: 48px 24px 80px; } .meta-tag { display: inline-block; font-size: 11px; font-weight: 600; letter-spacing: 0.12em; text-transform: uppercase; color: var(--text-green); background: var(--green-light); border: 1px solid var(--green-border); border-radius: 4px; padding: 3px 10px; margin-bottom: 18px; } h1 { font-family: 'Lora', Georgia, serif; font-size: clamp(26px, 4vw, 38px); font-weight: 600; line-height: 1.25; color: var(--text-primary); margin-bottom: 18px; letter-spacing: -0.01em; } .deck { font-size: 19px; line-height: 1.6; color: var(--text-muted); margin-bottom: 28px; border-bottom: 1px solid var(--border-soft); padding-bottom: 28px; } .illustration-wrap { margin: 8px 0 36px; border-radius: 10px; overflow: hidden; border: 1px solid var(--border-soft); background: var(--cream-dark); } .illustration-wrap svg { display: block; width: 100%; } .img-caption { font-size: 13px; color: var(--text-muted); padding: 10px 16px 12px; border-top: 1px solid var(--border-soft); font-style: italic; line-height: 1.6; } .toc-box { background: var(--cream-dark); border: 1px solid var(--border-soft); border-radius: 10px; padding: 20px 24px 24px; margin: 0 0 40px; } .toc-label { display: flex; align-items: center; gap: 8px; font-size: 11px; font-weight: 600; letter-spacing: 0.1em; text-transform: uppercase; color: var(--text-muted); margin-bottom: 14px; } .toc-label::before { content: ""; display: inline-block; width: 14px; height: 14px; background: var(--border-soft); border-radius: 2px; } .toc-box ol { list-style: none; padding: 0; display: flex; flex-direction: column; gap: 8px; } .toc-box ol li a { color: var(--text-green); text-decoration: none; font-size: 16px; font-weight: 500; border-bottom: 1px solid transparent; transition: border-color 0.15s; } .toc-box ol li a:hover { border-color: var(--green-mid); } .prose h2 { font-family: 'Lora', Georgia, serif; font-size: clamp(20px, 3vw, 26px); font-weight: 600; color: var(--text-primary); margin: 44px 0 6px; padding-bottom: 12px; border-bottom: 1px solid var(--border-soft); letter-spacing: -0.01em; } .prose p { font-family: 'Lora', Georgia, serif; font-size: 18px; line-height: 1.82; color: var(--text-body); margin-bottom: 16px; max-width: 68ch; } .prose p strong { font-weight: 600; color: var(--text-primary); } .prose p.impact { font-size: 19px; font-style: italic; color: var(--text-muted); border-left: 3px solid var(--green-mid); padding-left: 18px; margin: 24px 0; } / INLINE SOURCE / .source-inline { font-family: 'Source Sans 3', sans-serif; font-size: 12px; color: var(--text-muted); font-style: italic; margin: -8px 0 20px; line-height: 1.5; display: block; } / QUICK ANSWER / .quick-box { background: var(--green-light); border: 1.5px solid var(--green-border); border-radius: 10px; padding: 20px 24px 22px; margin: 20px 0 24px; } .quick-box .qa-label { font-size: 11px; font-weight: 600; letter-spacing: 0.1em; text-transform: uppercase; color: var(--amber); display: flex; align-items: center; gap: 6px; margin-bottom: 10px; } .quick-box .qa-label::before { content: "⚡"; font-size: 13px; } .quick-box .qa-question { font-family: 'Source Sans 3', sans-serif; font-weight: 600; font-size: 17px; color: var(--text-primary); margin-bottom: 10px; } .quick-box .qa-answer { font-family: 'Source Sans 3', sans-serif; font-size: 16px; line-height: 1.7; color: var(--text-body); } .quick-box .qa-answer strong { color: var(--text-primary); } / LANDMARK BOX / .landmark-box { background: #EEF4FB; border: 1px solid #B8D0E8; border-radius: 10px; padding: 18px 22px 20px; margin: 20px 0 8px; } .landmark-box .lm-label { font-family: 'Source Sans 3', sans-serif; font-size: 10px; font-weight: 600; letter-spacing: 0.1em; text-transform: uppercase; color: #3A6A9A; margin-bottom: 8px; } .landmark-box .lm-question { font-family: 'Source Sans 3', sans-serif; font-weight: 600; font-size: 16px; color: var(--text-primary); margin-bottom: 8px; line-height: 1.4; } .landmark-box .lm-answer { font-family: 'Source Sans 3', sans-serif; font-size: 15px; line-height: 1.72; color: var(--text-body); } .landmark-box .lm-answer strong { color: var(--text-primary); font-weight: 600; } / STAT STRIP / .stat-strip { display: grid; grid-template-columns: repeat(auto-fit, minmax(120px, 1fr)); border: 1px solid var(--border-soft); border-radius: 8px; overflow: hidden; margin: 18px 0 8px; } .stat-cell { padding: 14px 16px 16px; border-right: 1px solid var(--border-soft); } .stat-cell:last-child { border-right: none; } .stat-cell .stat-label { font-size: 10px; font-weight: 600; letter-spacing: 0.1em; text-transform: uppercase; color: var(--text-muted); margin-bottom: 5px; } .stat-cell .stat-val { font-size: 22px; font-weight: 600; color: var(--green-mid); font-family: 'Source Sans 3', sans-serif; line-height: 1.1; } / PHASE CARDS / .phase-list { display: flex; flex-direction: column; gap: 14px; margin: 20px 0 8px; } .phase-card { display: flex; gap: 0; background: #fff; border: 1px solid var(--border-soft); border-radius: 10px; overflow: hidden; } .phase-num { background: var(--green-dark); color: #fff; font-family: 'Source Sans 3', sans-serif; font-size: 11px; font-weight: 600; writing-mode: vertical-rl; text-orientation: mixed; display: flex; align-items: center; justify-content: center; padding: 16px 12px; flex-shrink: 0; min-width: 44px; letter-spacing: 0.06em; text-transform: uppercase; } .phase-content { padding: 16px 18px 18px; flex: 1; } .phase-content h4 { font-family: 'Source Sans 3', sans-serif; font-size: 15px; font-weight: 600; color: var(--text-primary); margin-bottom: 6px; } .phase-content .phase-sub { font-family: 'Source Sans 3', sans-serif; font-size: 11px; color: var(--amber); font-weight: 600; letter-spacing: 0.06em; text-transform: uppercase; margin-bottom: 8px; } .phase-content p { font-family: 'Source Sans 3', sans-serif; font-size: 14px; color: var(--text-muted); line-height: 1.65; margin: 0; max-width: none; } .phase-content p strong { color: var(--text-primary); } / COST TABLE / .cost-table { width: 100%; border-collapse: collapse; border: 1px solid var(--border-soft); border-radius: 8px; overflow: hidden; margin: 18px 0 8px; font-size: 14px; } .cost-table thead th { background: var(--cream-dark); padding: 11px 13px; text-align: left; font-size: 10px; font-weight: 600; letter-spacing: 0.07em; text-transform: uppercase; color: var(--text-muted); border-bottom: 1px solid var(--border-soft); } .cost-table thead th.india-head { background: var(--green-light); color: var(--green-dark); } .cost-table tbody td { padding: 11px 13px; border-bottom: 1px solid var(--border-soft); font-family: 'Source Sans 3', sans-serif; color: var(--text-body); line-height: 1.5; vertical-align: top; } .cost-table tbody tr:last-child td { border-bottom: none; } .cost-table tbody td:first-child { font-weight: 600; color: var(--text-primary); width: 32%; } .cost-table .highlight td { background: #FAFAF7; } .cost-table .saving { color: var(--green-mid); font-weight: 600; } .cost-table .saving-pct { display: inline-block; font-size: 11px; font-weight: 600; background: var(--green-light); color: var(--green-dark); border-radius: 4px; padding: 1px 6px; margin-left: 4px; } / HOSPITAL CARDS / .hospital-grid { display: flex; flex-direction: column; gap: 12px; margin: 20px 0 8px; } .hospital-card { border: 1px solid var(--border-soft); border-radius: 10px; padding: 16px 20px 18px; background: #fff; display: flex; gap: 16px; align-items: flex-start; } .hospital-rank { font-family: 'Source Sans 3', sans-serif; font-size: 22px; font-weight: 600; color: var(--green-border); line-height: 1; flex-shrink: 0; min-width: 28px; padding-top: 2px; } .hospital-info h4 { font-family: 'Source Sans 3', sans-serif; font-size: 16px; font-weight: 600; color: var(--text-primary); margin-bottom: 4px; } .hospital-info h4 a { color: var(--text-primary); text-decoration: none; border-bottom: 1px solid var(--green-border); } .hospital-info p { font-family: 'Source Sans 3', sans-serif; font-size: 14px; color: var(--text-muted); line-height: 1.6; margin: 0; max-width: none; } .hospital-info p strong { color: var(--text-primary); font-weight: 600; } / CALLOUTS / .callout-green { border-left: 3px solid var(--green-mid); background: var(--green-light); border-radius: 0 8px 8px 0; padding: 16px 20px 18px; margin: 20px 0; } .callout-green .callout-label { font-size: 11px; font-weight: 600; letter-spacing: 0.1em; text-transform: uppercase; color: var(--text-green); margin-bottom: 8px; } .callout-red { border-left: 3px solid var(--red-accent); background: var(--red-bg); border-radius: 0 8px 8px 0; padding: 16px 20px 18px; margin: 20px 0; } .callout-red .callout-label { font-size: 11px; font-weight: 600; letter-spacing: 0.1em; text-transform: uppercase; color: var(--red-accent); margin-bottom: 8px; } .callout-amber { border-left: 3px solid var(--amber); background: var(--amber-bg); border-radius: 0 8px 8px 0; padding: 16px 20px 18px; margin: 20px 0; } .callout-amber .callout-label { font-size: 11px; font-weight: 600; letter-spacing: 0.1em; text-transform: uppercase; color: var(--amber); margin-bottom: 8px; } .callout-green p, .callout-red p, .callout-amber p { font-size: 16px; line-height: 1.7; font-family: 'Source Sans 3', sans-serif; color: var(--text-body); margin: 0; max-width: none; } / CTAs */ .cta-a { background: var(--green-dark); border-radius: 12px; padding: 28px 28px 30px; margin: 32px 0; } .cta-a .cta-h { font-family: 'Source Sans 3', sans-serif; font-size: 18px; font-weight: 600; color: #fff; margin-bottom: 8px; line-height: 1.4; } .cta-a .cta-s { font-family: 'Source Sans 3', sans-serif; font-size: 15px; color: rgba(255,255,255,.78); margin-bottom: 20px; line-height: 1.6; } .btn-white { display: inline-block; background: #fff; color: var(--green-dark); font-family: 'Source Sans 3', sans-serif; font-size: 15px; font-weight: 600; padding: 11px 22px; border-radius: 6px; text-decoration: none; transition: background 0.15s; } .btn-white:hover { background: #e8f4ee; } .cta-b { border: 1.5px solid var(--green-border); background: #fff; border-radius: 10px; padding: 20px 22px 22px; margin: 24px 0; display: flex; flex-direction: column; gap: 10px; } .cta-b .cta-h { font-family: 'Source Sans 3', sans-serif; font-size: 16px; font-weight: 600; color: var(--text-primary); line-height: 1.4; } .cta-b .cta-s { font-family: 'Source Sans 3', sans-serif; font-size: 14px; color: var(--text-muted); line-height: 1.6; } .btn-green { display: inline-block; background: var(--green-dark); color: #fff; font-family: 'Source Sans 3', sans-serif; font-size: 14px; font-weight: 600; padding: 10px 20px; border-radius: 6px; text-decoration: none; align-self: flex-start; transition: background 0.15s; } .btn-green:hover { background: var(--green-mid); } .cta-c { display: flex; align-items: flex-start; gap: 14px; background: var(--cream-dark); border: 1px solid var(--border-soft); border-radius: 8px; padding: 16px 20px; margin: 20px 0; text-decoration: none; transition: border-color 0.15s, background 0.15s; } .cta-c:hover { background: var(--green-light); border-color: var(--green-border); } .cta-c .cta-arrow { font-size: 20px; color: var(--green-mid); line-height: 1; flex-shrink: 0; margin-top: 2px; } .cta-c .rl-label { font-size: 15px; color: var(--green-mid); font-weight: 600; margin-bottom: 4px; font-family: 'Source Sans 3', sans-serif; } .cta-c .rl-desc { font-size: 14px; color: var(--text-muted); font-family: 'Source Sans 3', sans-serif; line-height: 1.5; } @media (max-width: 600px) { .stat-strip { grid-template-columns: 1fr 1fr; } .cost-table { font-size: 13px; } .cost-table thead th, .cost-table tbody td { padding: 9px 10px; } .phase-card { flex-direction: column; } .phase-num { writing-mode: horizontal-tb; padding: 10px 16px; min-width: auto; } } </style> </head> <body> <div class="page-wrap">

<span class="meta-tag">Cervical Cancer · Radiation · Brachytherapy · India</span>

<h1>Radiation and Brachytherapy for Cervical Cancer: What India's Top Centres Actually Deliver</h1>

<p class="deck">Most patients are told they need "radiation and brachytherapy" and handed almost no information about what that actually means, what happens during treatment, or why the two parts together are so much more effective than either alone. This guide fills that gap — and explains why India delivers this treatment to a standard that most patients from Africa and South Asia simply cannot access at home.</p>

<div class="illustration-wrap"> <svg viewBox="0 0 700 220" xmlns="http://www.w3.org/2000/svg" role="img" aria-label="Medical diagram showing the two-part radiation treatment approach for cervical cancer. The left panel shows external beam radiation therapy (EBRT/IMRT) with a linear accelerator delivering converging beams from multiple angles to the pelvic tumour, with a dose distribution ellipse showing high dose at the tumour centre decreasing toward organs at risk including the bladder and rectum. The right panel shows HDR brachytherapy with an applicator placed inside the uterine cavity, delivering radiation from an iridium-192 source directly inside the tumour. An MRI planning image icon is shown to indicate image-guided adaptive planning at each fraction. Together these two modalities achieve local control rates of 85 to 90 percent in stage IIB cervical cancer when delivered to GEC-ESTRO standards."> <defs> <linearGradient id="bgRT2" x1="0" y1="0" x2="0" y2="1"> <stop offset="0%" stop-color="#EDE9DF"/><stop offset="100%" stop-color="#E4DFCF"/> </linearGradient> <radialGradient id="doseGrad2" cx="50%" cy="50%" r="50%"> <stop offset="0%" stop-color="#C05030" stop-opacity="0.65"/> <stop offset="45%" stop-color="#B07A15" stop-opacity="0.3"/> <stop offset="85%" stop-color="#2D7A52" stop-opacity="0.1"/> <stop offset="100%" stop-color="#2D7A52" stop-opacity="0"/> </radialGradient> </defs> <rect width="700" height="220" fill="url(#bgRT2)"/>

<text x="175" y="20" text-anchor="middle" font-family="'Source Sans 3',sans-serif" font-size="11" font-weight="600" fill="#8A5F10" letter-spacing="0.06em">EXTERNAL BEAM (EBRT / IMRT)</text> <text x="525" y="20" text-anchor="middle" font-family="'Source Sans 3',sans-serif" font-size="11" font-weight="600" fill="#1B5E3B" letter-spacing="0.06em">HDR BRACHYTHERAPY (INTERNAL)</text> <line x1="350" y1="12" x2="350" y2="208" stroke="#DDD9CF" stroke-width="1" stroke-dasharray="4 3"/>

<rect x="125" y="32" width="100" height="26" rx="6" fill="#C8C4BA" stroke="#A0A09A" stroke-width="1"/> <text x="175" y="50" text-anchor="middle" font-family="'Source Sans 3',sans-serif" font-size="10" fill="#fff" font-weight="600">LINEAR ACCELERATOR</text>  <line x1="155" y1="58" x2="142" y2="122" stroke="#D08820" stroke-width="1.5" stroke-dasharray="4 3" opacity="0.7"/> <line x1="175" y1="58" x2="175" y2="122" stroke="#D08820" stroke-width="1.5" stroke-dasharray="4 3" opacity="0.7"/> <line x1="195" y1="58" x2="208" y2="122" stroke="#D08820" stroke-width="1.5" stroke-dasharray="4 3" opacity="0.7"/>  <ellipse cx="175" cy="130" rx="52" ry="38" fill="url(#doseGrad2)"/> <circle cx="175" cy="130" r="11" fill="#C05030" opacity="0.75"/>  <text x="94" y="120" font-family="'Source Sans 3',sans-serif" font-size="9" fill="#6B6860">Bladder</text> <text x="222" y="142" font-family="'Source Sans 3',sans-serif" font-size="9" fill="#6B6860">Rectum</text>  <rect x="78" y="168" width="194" height="7" rx="3" fill="#C8C4BA"/>  <text x="175" y="194" text-anchor="middle" font-family="'Source Sans 3',sans-serif" font-size="10" fill="#8A5F10" font-weight="600">5 days/week · 5–6 weeks</text> <text x="175" y="208" text-anchor="middle" font-family="'Source Sans 3',sans-serif" font-size="10" fill="#6B6860">Multi-angle beams — spares bladder and rectum</text>

<ellipse cx="525" cy="128" rx="80" ry="68" fill="#F0EDE4" stroke="#C8C4BA" stroke-width="1.5"/> <ellipse cx="525" cy="104" rx="28" ry="30" fill="#FDE8D8" stroke="#D07040" stroke-width="1"/>  <line x1="525" y1="74" x2="525" y2="168" stroke="#2D7A52" stroke-width="3" stroke-linecap="round"/> <ellipse cx="525" cy="145" rx="20" ry="7" fill="none" stroke="#2D7A52" stroke-width="2"/>  <ellipse cx="525" cy="130" rx="34" ry="28" fill="#C05030" opacity="0.16"/> <ellipse cx="525" cy="130" rx="18" ry="16" fill="#C05030" opacity="0.34"/>  <circle cx="525" cy="118" r="4" fill="#C05030"/> <line x1="529" y1="114" x2="558" y2="96" stroke="#C05030" stroke-width="1" opacity="0.6"/> <text x="561" y="95" font-family="'Source Sans 3',sans-serif" font-size="9" fill="#C05030" font-weight="600">Ir-192 source</text>  <rect x="588" y="138" width="62" height="36" rx="5" fill="#EAF4EE" stroke="#C2DFCC" stroke-width="1"/> <text x="619" y="154" text-anchor="middle" font-family="'Source Sans 3',sans-serif" font-size="9" fill="#1B5E3B" font-weight="600">MRI</text> <text x="619" y="166" text-anchor="middle" font-family="'Source Sans 3',sans-serif" font-size="9" fill="#6B6860">planning</text>  <text x="525" y="194" text-anchor="middle" font-family="'Source Sans 3',sans-serif" font-size="10" fill="#1B5E3B" font-weight="600">4–6 fractions · 1–2 weeks</text> <text x="525" y="208" text-anchor="middle" font-family="'Source Sans 3',sans-serif" font-size="10" fill="#6B6860">Radiation delivered from inside — millimetres from tumour</text> </svg> <p class="img-caption">The two-part radiation approach for cervical cancer. External beam radiation (EBRT/IMRT, left) delivers converging beams from a linear accelerator, maximising tumour dose while sparing the bladder and rectum. HDR brachytherapy (right) places an applicator directly inside the uterus and vagina, delivering radiation from an iridium-192 source millimetres from the tumour centre. Together, these modalities achieve local control rates of 85–92% in stage IIB disease when delivered to GEC-ESTRO image-guided standards — the standard all four GAF Healthcare partner hospitals in India meet.</p> </div>

<div class="toc-box"> <div class="toc-label">What's in this guide</div> <ol> <li><a href="#why-radiation-central">Why radiation is the centrepiece of cervical cancer treatment</a></li> <li><a href="#ebrt">External beam radiation — what it involves and what India uses</a></li> <li><a href="#brachytherapy">Brachytherapy — the treatment most women cannot access at home</a></li> <li><a href="#igabt">Image-guided adaptive brachytherapy — the gold standard India delivers</a></li> <li><a href="#without-brachy">What happens when brachytherapy is omitted — the data is stark</a></li> <li><a href="#concurrent-chemo">Concurrent cisplatin — why chemotherapy runs alongside radiation</a></li> <li><a href="#side-effects">Side effects — what to expect honestly</a></li> <li><a href="#hospitals">Where to get this treatment in India</a></li> <li><a href="#cost">What it costs in India vs the US and UK</a></li> </ol> </div>

<h2 id="why-radiation-central">Why radiation is the centrepiece of cervical cancer treatment</h2>

<p>Cervical cancer is one of the most radiation-sensitive tumours in oncology. This is not a casual observation — it is the biological foundation of how the disease is treated worldwide.</p>

<p>For stage IB2 and above, concurrent chemoradiation followed by brachytherapy is the internationally recommended standard of care. Not surgery. Not chemotherapy alone. Radiation in its complete, two-part form.</p>

<p>The reason surgery gives way to radiation at this stage is both clinical and anatomical. Once the tumour has grown large or spread to the parametrial tissue, a radiation field can treat regional lymph nodes and microscopic spread that surgery cannot reach. The radiation also does not require clear margins around every millimetre of involved tissue in the way surgery does — it is inherently more suited to the geometry of locally advanced disease.</p>

<span class="source-inline">Sources: Landoni F et al., "Randomised study of radical surgery versus radiotherapy for stage Ib–IIa cervical cancer," The Lancet, 1997 · NCCN Clinical Practice Guidelines — Cervical Cancer v1.2025 · ESMO Clinical Practice Guidelines: Cervical Cancer, Ann Oncol, 2018</span>

<p>What makes cervical cancer treatment uniquely demanding — and uniquely dependent on infrastructure — is that external beam radiation alone is not sufficient. Brachytherapy alone is not sufficient. The two work together: external beam treats the full pelvis and regional nodes, brachytherapy delivers a concentrated tumour-killing dose from within. Remove either component and the treatment is incomplete.</p>

<p>This is the clinical reality that drives women from across Africa and South Asia to seek treatment in India — where both components are delivered, together, to GEC-ESTRO international standards.</p>

<div class="quick-box"> <div class="qa-label">Quick answer</div> <div class="qa-question">Is external beam radiation alone enough to cure cervical cancer?</div> <div class="qa-answer">No — not for most stage II and III patients. A National Cancer Database analysis of over 7,800 women found that patients who received brachytherapy in addition to EBRT had <strong>four-year overall survival of 64%</strong>, compared to 51% for EBRT alone — a 13-percentage-point difference from one treatment decision. Omitting brachytherapy is one of the most consequential errors in cervical cancer treatment. All four GAF Healthcare partner hospitals in India include brachytherapy as standard for every eligible patient.</div> </div> <span class="source-inline">Source: Gill BS et al., "National Cancer Data Base analysis of radiation therapy consolidation modality for cervical cancer," International Journal of Radiation Oncology Biology Physics, 2014</span>

<h2 id="ebrt">External beam radiation — what it involves and what India uses</h2>

<p>External beam radiation therapy (EBRT) for cervical cancer is delivered by a linear accelerator — a machine that generates high-energy X-ray beams and directs them at the pelvis from multiple angles outside the body.</p>

<p>The standard course runs five days per week for five to six weeks — 25 to 28 fractions. Each session takes 15 to 20 minutes and is painless. The patient lies still on a treatment table while the machine rotates, delivering calculated beams that maximise dose to the tumour while reducing dose to the bladder, rectum, and small bowel.</p>

<p>The technique used matters enormously. India's top cancer centres use <strong>intensity-modulated radiation therapy (IMRT)</strong> or its rotational variant VMAT — the most precise form of external beam delivery currently in clinical use. Conventional four-field box radiation — still used at some lower-resource centres — delivers higher doses to surrounding healthy tissue and produces more side effects for equivalent tumour coverage.</p>

<span class="source-inline">Source: Mundt AJ et al., "Intensity-modulated whole pelvic radiotherapy in women with gynecologic malignancies," International Journal of Radiation Oncology Biology Physics, 2002</span>

<div class="landmark-box"> <div class="lm-label">📋 Landmark Evidence — NRG Oncology / RTOG 1203</div> <div class="lm-question">Does IMRT actually reduce toxicity compared to conventional radiation in cervical cancer?</div> <div class="lm-answer">Yes — and significantly. The NRG Oncology / RTOG 1203 trial directly compared IMRT versus standard four-field pelvic radiation in patients with cervical and endometrial cancer. IMRT produced <strong>significantly lower rates of acute gastrointestinal toxicity</strong>: 37% of IMRT patients reported significant diarrhoea versus 61% on conventional radiation. Bowel urgency and use of anti-diarrhoeal medications were also substantially reduced. The trial confirmed IMRT as the preferred standard for pelvic radiation in gynaecological cancers at high-volume centres. All four GAF Healthcare partner hospitals use IMRT or VMAT as their routine technique.</div> </div> <span class="source-inline">Source: Klopp AH et al., "Patient-reported toxicity during pelvic intensity-modulated radiation therapy: NRG Oncology-RTOG 1203," Journal of Clinical Oncology, 2018</span>

<p>The radiation field for cervical cancer covers the primary tumour, the cervix and uterus, the parametrial tissue, the upper vagina, and the pelvic lymph node chains. For stage IIIC2 disease — where para-aortic nodes are involved — the field extends further upward. This extended-field radiation is available at all four GAF Healthcare partner hospitals.</p>

<div class="cta-b"> <p class="cta-h">Recommended chemoradiation and want to understand what the treatment involves?</p> <p class="cta-s">Share your stage and diagnosis. Our coordinators will walk you through the full sequence — what happens each week, how brachytherapy works, how long you need to be in India, and what it costs. At no charge, within 24 hours.</p> <a href="https://gafhealthcare.in/contact" class="btn-green">Get a Free Treatment Walkthrough →</a> </div>

<h2 id="brachytherapy">Brachytherapy — the treatment most women cannot access at home</h2>

<p>If there is one sentence that explains why women travel from Nigeria, Ghana, Kenya, Tanzania, and Zambia to India for cervical cancer treatment, it is this: brachytherapy is unavailable in the majority of sub-Saharan African public hospitals, and external beam radiation alone is not curative for most stage II and III cervical cancers.</p>

<p>Brachytherapy means radiation from the inside. An applicator — a set of tubes and rings — is placed inside the uterus and vaginal vault under anaesthesia. A radioactive source, typically iridium-192, travels along the applicator and pauses at calculated positions inside the tumour, delivering a precisely targeted dose of radiation from within millimetres of the cancer cells.</p>

<p>The result is a dose distribution that external beam radiation cannot replicate. The tumour receives an extremely high, focused dose. The surrounding bladder and rectum — highly sensitive to radiation damage — receive dramatically lower doses than would be achievable from outside the body.</p>

<span class="source-inline">Sources: Pötter R et al., "Clinical outcome of protocol based image-guided adaptive brachytherapy combined with 3D conformal radiotherapy with or without chemotherapy in patients with locally advanced cervical cancer," Radiotherapy and Oncology, 2011 · Haie-Meder C et al., GEC-ESTRO Working Group recommendations for brachytherapy for cervical carcinoma, Radiotherapy and Oncology, 2005</span>

<div class="callout-red"> <div class="callout-label">The brachytherapy machine crisis across Africa</div> <p>The International Atomic Energy Agency estimates that fewer than 20 operational brachytherapy units exist across all of sub-Saharan Africa — serving a population of over one billion people. Many of these units are intermittently out of service. A woman diagnosed with stage IIB cervical cancer in <a href="https://gafhealthcare.in/nigeria/treatment-in-india" style="color:var(--red-accent);text-decoration:underline;text-decoration-color:#E8BABA;">Nigeria</a>, <a href="https://gafhealthcare.in/ghana/treatment-in-india" style="color:var(--red-accent);text-decoration:underline;text-decoration-color:#E8BABA;">Ghana</a>, <a href="https://gafhealthcare.in/tanzania/treatment-in-india" style="color:var(--red-accent);text-decoration:underline;text-decoration-color:#E8BABA;">Tanzania</a>, or <a href="https://gafhealthcare.in/zambia/treatment-in-india" style="color:var(--red-accent);text-decoration:underline;text-decoration-color:#E8BABA;">Zambia</a> has, in most cases, one realistic path to the complete treatment: travel to India. This is not a fringe option — it is the clinically correct decision, and it is what GAF Healthcare facilitates every week.</p> </div> <span class="source-inline">Sources: IAEA Division of Human Health, Global Brachytherapy Programme Status Report, 2023 · Atun R et al., "Expanding global access to radiotherapy," The Lancet Oncology, 2015</span>

<h2 id="igabt">Image-guided adaptive brachytherapy — the gold standard India delivers</h2>

<p>Not all brachytherapy is equal. This deserves to be said clearly, because patients sometimes assume that any centre offering brachytherapy is offering equivalent treatment.</p>

<p>The gold standard — established by the GEC-ESTRO Working Group and now adopted by NCCN, ESMO, and every major cervical cancer guideline body — is <strong>image-guided adaptive brachytherapy (IGABT)</strong>. It uses MRI or CT imaging at each brachytherapy fraction to plan the dose specifically for that session, accounting for how the tumour has changed in response to the preceding external beam radiation.</p>

<p>Point-based brachytherapy — the older technique, still used at some lower-resource centres — applies the same dose geometry to every fraction, regardless of tumour response. It is less precise. It produces inferior tumour coverage and higher long-term toxicity rates to the bladder and rectum.</p>

<span class="source-inline">Sources: Pötter R et al., "Recommendations from gynaecological GEC-ESTRO working group (IV): Basic principles and parameters for MR imaging within the frame of adaptive radiotherapy of cervical cancer," Radiotherapy and Oncology, 2012 · Tanderup K et al., "Improvement of local tumour control probability with adaptive target volume definition in MRI-guided brachytherapy," Radiotherapy and Oncology, 2014</span>

<div class="landmark-box"> <div class="lm-label">📋 Landmark Evidence — EMBRACE-I Study, Lancet Oncology 2021</div> <div class="lm-question">What does MRI-guided adaptive brachytherapy actually achieve in real-world practice?</div> <div class="lm-answer">The EMBRACE-I study — the largest prospective multicentre study of image-guided brachytherapy ever conducted, covering 1,416 patients across 25 specialist centres — found that IGABT achieved a <strong>five-year local tumour control rate of 92%</strong> for stage IIB disease. Serious late bladder complications occurred in fewer than 5% of patients, and serious bowel complications in fewer than 5% — substantially lower than historical rates with point-based brachytherapy. The study confirmed that IGABT is both more effective and significantly less toxic than older approaches. This is the standard all four GAF Healthcare partner hospitals in India are trained and equipped to deliver.</div> </div> <span class="source-inline">Source: Pötter R et al., "Prospective multicentre study of MRI-guided adaptive brachytherapy in locally advanced cervical cancer: Final analysis of the EMBRACE-I study," The Lancet Oncology, 2021</span>

<p>What IGABT requires — and what makes it unavailable at most centres globally — is an MRI scanner accessible for brachytherapy planning, trained radiation oncologists who understand adaptive planning, a physicist capable of replanning at each fraction, and a brachytherapy suite with appropriate applicator systems. This is not a trivial infrastructure requirement.</p>

<p>It is, however, exactly what you get at <a href="https://gafhealthcare.in/hospitals/tata-memorial-hospital-mumbai" style="color:var(--green-mid);text-decoration:underline;text-decoration-color:var(--green-border);">Tata Memorial Hospital</a>, <a href="https://gafhealthcare.in/hospitals/apollo-hospitals-new-delhi" style="color:var(--green-mid);text-decoration:underline;text-decoration-color:var(--green-border);">Apollo</a>, <a href="https://gafhealthcare.in/hospitals/medanta-the-medicity-gurgaon" style="color:var(--green-mid);text-decoration:underline;text-decoration-color:var(--green-border);">Medanta</a>, and <a href="https://gafhealthcare.in/hospitals/fortis-memorial-research-institute-gurgaon" style="color:var(--green-mid);text-decoration:underline;text-decoration-color:var(--green-border);">Fortis Memorial</a>.</p>

<p class="impact">"We do not plan brachytherapy once and repeat it. We plan it fresh at every fraction — because the tumour on day 28 of radiation is not the same tumour it was on day one. That adaptive approach is what the EMBRACE data shows."</p>

<div class="cta-a"> <p class="cta-h">Told you need brachytherapy but your local centre does not offer it?</p> <p class="cta-s">You are not alone — this is one of the most common situations GAF Healthcare handles. Share your diagnosis and stage, and we will outline the full treatment course, how long you need to be in India, and what it costs. At no charge, within 24 hours.</p> <a href="https://gafhealthcare.in/contact" class="btn-white">Get My Brachytherapy Plan →</a> </div>

<h2 id="without-brachy">What happens when brachytherapy is omitted — the data is stark</h2>

<p>Some patients receive external beam radiation without brachytherapy — either because their local centre does not have the equipment, or because they are told that external beam alone is sufficient. The evidence on what this means for survival should be part of every conversation a patient has with their oncologist.</p>

<p>A 2013 study in the International Journal of Radiation Oncology Biology Physics analysed 7,359 women with locally advanced cervical cancer treated across the United States. It found that patients who did not receive brachytherapy had <strong>significantly worse survival</strong> — and crucially, that the proportion of patients receiving brachytherapy had actually declined over time at lower-volume centres, despite the evidence being clear.</p>

<span class="source-inline">Source: Han K et al., "Trends in the utilisation of brachytherapy in cervical cancer in the United States," International Journal of Radiation Oncology Biology Physics, 2013</span>

<p>The National Cancer Database analysis confirmed this with even larger numbers. Over 7,800 patients. EBRT plus brachytherapy: 64% four-year overall survival. EBRT alone: 51%. That is a 13-percentage-point survival difference from a single treatment decision — a magnitude comparable to adding a major systemic drug.</p>

<span class="source-inline">Source: Gill BS et al., "National Cancer Data Base analysis of radiation therapy consolidation modality for cervical cancer," International Journal of Radiation Oncology Biology Physics, 2014</span>

<div class="callout-amber"> <div class="callout-label">If you have already received EBRT without brachytherapy</div> <p>If you completed external beam radiation for cervical cancer but did not receive brachytherapy — because your centre lacked the equipment or because you were told it was unnecessary — share your treatment records with GAF Healthcare before accepting that outcome. In some situations, a brachytherapy boost can still be delivered depending on time elapsed, tumour response, and dose already received. India's radiation oncologists at Tata Memorial and Apollo have experience with these complex situations. A remote second opinion costs nothing and may change the trajectory significantly.</p> </div>

<h2 id="concurrent-chemo">Concurrent cisplatin — why chemotherapy runs alongside radiation</h2>

<p>Concurrent chemoradiation — radiation combined with weekly cisplatin — is the standard for stage IB2 and above. But cisplatin here is not being used as conventional chemotherapy to kill cancer cells systemically. It is used at a low dose — 40 mg/m² weekly — specifically to make cancer cells more sensitive to radiation. It is a radiosensitiser.</p>

<p>The cisplatin enters cancer cells, damages their DNA repair mechanisms, and prevents them from recovering from the radiation injury between fractions. The result is more cancer cell death per Gray of radiation dose delivered.</p>

<span class="source-inline">Source: Begg AC, "Cisplatin and radiation: interaction probabilities and therapeutic possibilities," International Journal of Radiation Oncology Biology Physics, 1990</span>

<div class="landmark-box"> <div class="lm-label">📋 Landmark Evidence — Five concurrent chemoradiation trials, Lancet 2001</div> <div class="lm-question">How much does adding cisplatin to radiation improve survival in cervical cancer?</div> <div class="lm-answer">A meta-analysis of five randomised controlled trials — covering 1,774 patients — found that concurrent cisplatin-based chemoradiation reduced the risk of death by <strong>30% compared to radiation alone</strong> (hazard ratio 0.71, p=0.002). This translated to an absolute improvement in five-year overall survival of approximately 6 percentage points. The benefit was consistent across all stages and tumour sizes included in the trials. Weekly cisplatin at 40 mg/m² during external beam radiation is now mandated in NCCN, ESMO, and FIGO treatment guidelines for locally advanced cervical cancer.</div> </div> <span class="source-inline">Source: Green JA et al., "Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis," The Lancet, 2001 · Updated Cochrane Collaboration systematic review, Vale C et al., 2010</span>

<p>In India, cisplatin costs approximately $30–$80 per weekly dose. Over a standard six-week concurrent chemoradiation course, the total cisplatin drug cost is $180–$480. In the United States, the same course runs $2,400–$7,200. The molecule, the dose, and the protocol are identical.</p>

<span class="source-inline">Source: GAF Healthcare hospital network pharmacy data, 2025–2026 · FAIR Health US Chemotherapy Drug Cost Database, 2024</span>

<h2 id="side-effects">Side effects — what to expect honestly</h2>

<p>Concurrent chemoradiation for cervical cancer is a significant treatment. The side effects are real and should be discussed honestly — not minimised, and not catastrophised. Most are manageable. Most resolve. Some persist long-term at low grade.</p>

<div class="phase-list"> <div class="phase-card"> <div class="phase-num">During EBRT</div> <div class="phase-content"> <div class="phase-sub">Weeks 1–6 of external beam radiation</div> <h4>Fatigue, bowel changes, perineal skin reaction</h4> <p><strong>Fatigue</strong> is the most consistent side effect — most patients feel tired by week three and it peaks in weeks five and six. <strong>Loose stools and bowel frequency</strong> occur in most patients — IMRT significantly reduces severity compared to conventional radiation. <strong>Perineal skin redness</strong> is common and managed with topical creams. These effects begin to resolve within two to four weeks of completing EBRT.</p> </div> </div> <div class="phase-card"> <div class="phase-num">During Cisplatin</div> <div class="phase-content"> <div class="phase-sub">Weekly intravenous infusion alongside radiation</div> <h4>Nausea, kidney monitoring, blood counts</h4> <p><strong>Nausea</strong> is common on infusion days — managed with anti-emetics before and after. <strong>Kidney function</strong> is monitored weekly — cisplatin can affect renal function and the dose is adjusted or held if needed. <strong>Blood counts</strong> are checked weekly — white cell counts may fall but serious neutropenia is uncommon at the weekly low-dose schedule used.</p> </div> </div> <div class="phase-card"> <div class="phase-num">During Brachy</div> <div class="phase-content"> <div class="phase-sub">4–6 fractions over 1–2 weeks</div> <h4>Applicator insertion, pelvic pressure, brief admissions</h4> <p>Each fraction involves <strong>applicator insertion</strong> under sedation or general anaesthesia — 30–60 minutes. The radiation source is then delivered over 10–20 minutes while the patient lies still. Most patients describe <strong>pelvic pressure and cramping</strong> during insertion, managed with analgesia. Between fractions, most patients feel well and can move around the hospital or nearby accommodation normally.</p> </div> </div> <div class="phase-card"> <div class="phase-num">Long-term</div> <div class="phase-content"> <div class="phase-sub">Months after treatment ends</div> <h4>Vaginal changes, bowel adjustment, fatigue resolution</h4> <p><strong>Vaginal dryness and stenosis</strong> occur in most women — managed with vaginal dilators (started three to four weeks after brachytherapy) and lubricants. <strong>Bowel frequency and looseness</strong> persist in approximately 20–30% of patients at one year but improve progressively. <strong>Fatigue</strong> resolves over two to four months. Serious late complications — significant bladder or bowel injury — occur in fewer than 5% with modern IGABT, and in substantially higher rates with older point-based techniques.</p> </div> </div> </div> <span class="source-inline">Sources: EMBRACE-I study late toxicity outcomes — Pötter R et al., Lancet Oncology, 2021 · Klopp AH et al., NRG/RTOG 1203 patient-reported toxicity outcomes, JCO, 2018</span>

<h2 id="hospitals">Where to get this treatment in India</h2>

<p>Not every hospital in India that offers brachytherapy delivers it to GEC-ESTRO image-guided adaptive standards. GAF Healthcare works only with centres that have demonstrated MRI-planned adaptive brachytherapy as their routine practice — not as an occasional capability.</p>

<div class="hospital-grid"> <div class="hospital-card"> <div class="hospital-rank">01</div> <div class="hospital-info"> <h4><a href="https://gafhealthcare.in/hospitals/tata-memorial-hospital-mumbai">Tata Memorial Hospital — Mumbai</a></h4> <p>India's highest-volume cervical cancer radiation centre. Tata Memorial's brachytherapy programme treats more cervical cancer patients annually than most national cancer systems in Europe. The radiation oncology team publishes on IGABT outcomes in international peer-reviewed journals and contributes to GEC-ESTRO guideline development. <strong>First choice for any stage II–IV patient</strong> requiring the complete chemoradiation and brachytherapy protocol — particularly for complex, large-volume, or IIIC disease.</p> </div> </div> <div class="hospital-card"> <div class="hospital-rank">02</div> <div class="hospital-info"> <h4><a href="https://gafhealthcare.in/hospitals/apollo-hospitals-new-delhi">Apollo Hospitals — New Delhi</a></h4> <p>Full IMRT/VMAT external beam and HDR brachytherapy with MRI-based adaptive planning. Apollo's radiation oncology team trained at leading Western institutions. <strong>Strongest international patient infrastructure</strong> of any Indian private hospital — multilingual coordinators, Arabic and Swahili support, and established accommodation near the hospital for the full seven to eight week treatment course. Consistently reliable for patients from West and East Africa and the Gulf.</p> </div> </div> <div class="hospital-card"> <div class="hospital-rank">03</div> <div class="hospital-info"> <h4><a href="https://gafhealthcare.in/hospitals/medanta-the-medicity-gurgaon">Medanta — The Medicity, Gurgaon</a></h4> <p>Full image-guided brachytherapy programme. Medanta's radiation oncology team has a strong track record with patients from <a href="https://gafhealthcare.in/nigeria/treatment-in-india" style="color:var(--green-mid);text-decoration:underline;text-decoration-color:var(--green-border);">Nigeria</a>, <a href="https://gafhealthcare.in/kenya/treatment-in-india" style="color:var(--green-mid);text-decoration:underline;text-decoration-color:var(--green-border);">Kenya</a>, <a href="https://gafhealthcare.in/bangladesh/treatment-in-india" style="color:var(--green-mid);text-decoration:underline;text-decoration-color:var(--green-border);">Bangladesh</a>, and the Gulf. <strong>On-campus accommodation</strong> within the Medanta complex makes logistics of the seven to eight week stay significantly more manageable. 25 minutes from Delhi international airport.</p> </div> </div> <div class="hospital-card"> <div class="hospital-rank">04</div> <div class="hospital-info"> <h4><a href="https://gafhealthcare.in/hospitals/fortis-memorial-research-institute-gurgaon">Fortis Memorial Research Institute — Gurgaon</a></h4> <p>Full radiation oncology infrastructure including IMRT and HDR brachytherapy. Weekly gynaecological oncology tumour board reviews every cervical cancer case before radiation planning begins. <strong>Strong choice for patients needing both surgery and radiation</strong> — those who undergo radical hysterectomy with positive nodes requiring adjuvant chemoradiation — as the surgical and radiation teams work in the same institution without referral gaps or scheduling delays.</p> </div> </div> </div> <span class="source-inline">Sources: Tata Memorial Hospital Annual Report 2023 · Apollo Hospitals Oncology Programme Data 2024 · GAF Healthcare hospital network clinical assessment, 2025</span>

<a href="https://gafhealthcare.in/treatments/cervical-cancer-treatment" class="cta-c"> <div class="cta-arrow">→</div> <div> <div class="rl-label">Full Cervical Cancer Treatment Guide — GAF Healthcare</div> <div class="rl-desc">Surgery, chemoradiation, brachytherapy, immunotherapy, costs, and the complete logistics of arranging cervical cancer treatment in India from your country.</div> </div> </a>

<h2 id="cost">What radiation and brachytherapy cost in India vs the US and UK</h2>

<p>The cost difference for radiation specifically is one of the largest in all of cancer medicine. A linear accelerator in the US carries institutional overhead — equipment amortisation, physicist salaries, liability insurance, quality assurance programmes — that pushes per-fraction costs to multiples of what the physics of the treatment actually requires.</p>

<p>India's same equipment runs at a fraction of that overhead. The result is not a minor discount. It is a structural difference of 88–92%.</p>

<table class="cost-table"> <thead> <tr> <th>Treatment component</th> <th>USA</th> <th>UK (private)</th> <th class="india-head">India ✦</th> </tr> </thead> <tbody> <tr> <td>EBRT full course — IMRT (25–28 fractions)</td> <td>$40,000–$100,000</td> <td>£18,000–£45,000</td> <td class="saving">$4,500–$9,000 <span class="saving-pct">~91% less</span></td> </tr> <tr class="highlight"> <td>Extended-field EBRT (pelvis + para-aortic nodes)</td> <td>$55,000–$120,000</td> <td>£22,000–£55,000</td> <td class="saving">$5,500–$11,000 <span class="saving-pct">~90% less</span></td> </tr> <tr> <td>HDR brachytherapy — per fraction (with planning)</td> <td>$3,000–$8,000</td> <td>£1,500–£4,000</td> <td class="saving">$400–$800 <span class="saving-pct">~90% less</span></td> </tr> <tr class="highlight"> <td>HDR brachytherapy — full course (4–6 fractions, MRI-planned)</td> <td>$15,000–$35,000</td> <td>£8,000–£18,000</td> <td class="saving">$2,000–$4,500 <span class="saving-pct">~88% less</span></td> </tr> <tr> <td>IGABT (MRI-guided adaptive, full course)</td> <td>$20,000–$45,000</td> <td>£10,000–£22,000</td> <td class="saving">$2,500–$5,500 <span class="saving-pct">~88% less</span></td> </tr> <tr class="highlight"> <td>Concurrent cisplatin — full 6-week course</td> <td>$2,400–$7,200</td> <td>£1,200–£3,600</td> <td class="saving">$180–$480 <span class="saving-pct">~94% less</span></td> </tr> <tr> <td>Radiation planning CT + MRI simulation</td> <td>$2,000–$5,000</td> <td>£1,000–£2,500</td> <td class="saving">$200–$500 <span class="saving-pct">~92% less</span></td> </tr> <tr class="highlight"> <td>Complete chemoradiation + brachytherapy (stage II–III)</td> <td>$80,000–$180,000</td> <td>£35,000–£80,000</td> <td class="saving">$8,000–$18,000 <span class="saving-pct">~90% less</span></td> </tr> </tbody> </table> <span class="source-inline">✦ India figures from GAF Healthcare hospital network, 2025–2026. Includes all fractions, adaptive planning, cisplatin infusions, hospital stay during brachytherapy, and oncology consultations. US: FAIR Health radiation oncology national database, 2024. UK: NHS reference costs and private sector published rates.</span>

<div class="stat-strip"> <div class="stat-cell"><div class="stat-label">Full treatment saving vs USA</div><div class="stat-val">~90%</div></div> <div class="stat-cell"><div class="stat-label">Full treatment saving vs UK</div><div class="stat-val">~80%</div></div> <div class="stat-cell"><div class="stat-label">IGABT India vs USA</div><div class="stat-val">~88% less</div></div> <div class="stat-cell"><div class="stat-label">Cisplatin saving India</div><div class="stat-val">~94% less</div></div> </div>

<div class="callout-green"> <div class="callout-label">What every GAF Healthcare radiation cost estimate includes</div> <p>Every cost estimate we provide covers the complete radiation episode — all EBRT fractions, all brachytherapy fractions with MRI-based adaptive planning at each session, applicator costs, anaesthesia for brachytherapy insertions, hospital stay during brachytherapy, weekly cisplatin infusions and monitoring blood tests, and all radiation oncology consultations throughout. There are no separate physicist charges or planning fees billed outside the total. You know the full number before you travel.</p> </div>

<p>For patients from <a href="https://gafhealthcare.in/nigeria/treatment-in-india" style="color:var(--green-mid);text-decoration:underline;text-decoration-color:var(--green-border);">Nigeria</a>, <a href="https://gafhealthcare.in/ghana/treatment-in-india" style="color:var(--green-mid);text-decoration:underline;text-decoration-color:var(--green-border);">Ghana</a>, <a href="https://gafhealthcare.in/kenya/treatment-in-india" style="color:var(--green-mid);text-decoration:underline;text-decoration-color:var(--green-border);">Kenya</a>, <a href="https://gafhealthcare.in/tanzania/treatment-in-india" style="color:var(--green-mid);text-decoration:underline;text-decoration-color:var(--green-border);">Tanzania</a>, <a href="https://gafhealthcare.in/zambia/treatment-in-india" style="color:var(--green-mid);text-decoration:underline;text-decoration-color:var(--green-border);">Zambia</a>, and <a href="https://gafhealthcare.in/bangladesh/treatment-in-india" style="color:var(--green-mid);text-decoration:underline;text-decoration-color:var(--green-border);">Bangladesh</a>, $8,000–$18,000 for the complete chemoradiation and brachytherapy course is a realistic family financial goal. It is not trivial. But it is achievable in a way that $80,000–$180,000 in the United States simply is not.</p>

<p>And it delivers the same treatment — the same IMRT, the same MRI-guided brachytherapy, the same weekly cisplatin, the same GEC-ESTRO protocol — that a patient at Memorial Sloan Kettering or the Royal Marsden receives.</p>

<div class="cta-b"> <p class="cta-h">Want an itemised cost breakdown for your specific stage and treatment course?</p> <p class="cta-s">Share your FIGO stage, any existing imaging, and diagnosis details. We will send an itemised estimate — EBRT fractions, brachytherapy, cisplatin, hospital stay — from 2–3 shortlisted Indian hospitals within 24 hours. At no charge.</p> <a href="https://gafhealthcare.in/contact" class="btn-green">Get My Cost Estimate →</a> </div>

<div class="cta-a"> <p class="cta-h">Ready to arrange radiation and brachytherapy in India?</p> <p class="cta-s">Share your diagnosis, stage, and any existing reports. Our medical team will confirm the treatment protocol for your case, recommend the right hospital, give you an honest cost estimate, and walk you through the full logistics — at no charge, within 24 hours.</p> <a href="https://gafhealthcare.in/contact" class="btn-white">Start My Free Consultation →</a> </div>

<a href="https://gafhealthcare.in/treatments/cervical-cancer-treatment" class="cta-c"> <div class="cta-arrow">→</div> <div> <div class="rl-label">Full Cervical Cancer Treatment Guide — GAF Healthcare</div> <div class="rl-desc">Surgery, chemoradiation, brachytherapy, immunotherapy, costs, and the complete logistics guide for international patients planning cervical cancer treatment in India.</div> </div> </a>

</div> </div> </body> </html>